Savara's NanoCluster dry powder aerosol drug delivery platform has potential for local or systemic delivery of a wide variety of drugs. Savara says that since it can precisely tailor its microparticles' sizes, it will improve aerosol efficiency, and thus will be able to deliver two to three times more drug to the lung than competitors' products.
3925 West Braker Lane
Austin, TX 78759
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
